ESMO 2014: Poster Session: REBECCA

by Denys Wheatley: A large cohort study of Regorafenib (REG) in the real-life setting in patients previously treated for metastatic colorectal cancer
This poster communication headed by David Tougeron’s group (Poitiers, France) has looked at a multi-kinase inhibitor called regorafenib (REG) in cases with pre-treated mCRC (part of a phase III CORRECT trial). The problem in this real-life setting as opposed to a selected population in a conventional clinical trial is recognised in trying to evaluate REG, which is now being done in the REBECCA study – regorafenibin metastatic  colorectal cancer: a french compassionate program. On baseline patient and tumour characteristics, dose and its intensity, adverse effects, pre and post treatments, predictors of events and data such as OS and PFS were obtained from 1119 enrolled patients that received REG (mostly 160 mg daily). These patients were under the management of no less than 283 physicians. Almost half had KRAS^mut. With a median age of 64 years, median time since diagnosis was 2.7 years, the majority having metastases in the liver or lungs.  In relation to the CORRECT study, this is the largest cohort on REG, and further analysis in this setting will provide valuable insight into the drug’s therapeutic efficacy in a real-life setting.